X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WYETH LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WYETH LTD AUROBINDO PHARMA/
WYETH LTD
 
P/E (TTM) x 15.7 27.7 56.7% View Chart
P/BV x 4.0 5.3 75.4% View Chart
Dividend Yield % 0.4 1.3 30.4%  

Financials

 AUROBINDO PHARMA   WYETH LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
WYETH LTD
Mar-13
AUROBINDO PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs8951,044 85.7%   
Low Rs622818 76.0%   
Sales per share (Unadj.) Rs254.6298.6 85.3%  
Earnings per share (Unadj.) Rs39.357.2 68.6%  
Cash flow per share (Unadj.) Rs46.658.4 79.7%  
Dividends per share (Unadj.) Rs2.5017.00 14.7%  
Dividend yield (eoy) %0.31.8 18.1%  
Book value per share (Unadj.) Rs160.0249.5 64.1%  
Shares outstanding (eoy) m585.8822.72 2,578.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.1 95.5%   
Avg P/E ratio x19.316.3 118.7%  
P/CF ratio (eoy) x16.315.9 102.2%  
Price / Book Value ratio x4.73.7 127.0%  
Dividend payout %6.429.7 21.4%   
Avg Mkt Cap Rs m444,39021,157 2,100.5%   
No. of employees `00014.00.5 2,841.9%   
Total wages/salary Rs m17,678400 4,419.4%   
Avg. sales/employee Rs Th10,667.813,787.4 77.4%   
Avg. wages/employee Rs Th1,264.3813.0 155.5%   
Avg. net profit/employee Rs Th1,645.82,643.3 62.3%   
INCOME DATA
Net Sales Rs m149,1576,783 2,198.9%  
Other income Rs m1,159353 328.7%   
Total revenues Rs m150,3167,136 2,106.4%   
Gross profit Rs m34,3431,617 2,123.5%  
Depreciation Rs m4,27627 16,076.3%   
Interest Rs m6676 12,130.9%   
Profit before tax Rs m30,5581,938 1,577.0%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m7,597632 1,201.6%   
Profit after tax Rs m23,0121,301 1,769.5%  
Gross profit margin %23.023.8 96.6%  
Effective tax rate %24.932.6 76.2%   
Net profit margin %15.419.2 80.5%  
BALANCE SHEET DATA
Current assets Rs m92,0626,984 1,318.2%   
Current liabilities Rs m66,2232,056 3,221.1%   
Net working cap to sales %17.372.6 23.8%  
Current ratio x1.43.4 40.9%  
Inventory Days Days10699 106.8%  
Debtors Days Days6824 282.7%  
Net fixed assets Rs m62,919244 25,754.6%   
Share capital Rs m586227 257.9%   
"Free" reserves Rs m93,1335,441 1,711.8%   
Net worth Rs m93,7195,668 1,653.5%   
Long term debt Rs m1,81425 7,256.0%   
Total assets Rs m162,4947,901 2,056.6%  
Interest coverage x46.8353.3 13.2%   
Debt to equity ratio x00 438.8%  
Sales to assets ratio x0.90.9 106.9%   
Return on assets %14.616.5 88.2%  
Return on equity %24.622.9 107.0%  
Return on capital %32.734.0 96.2%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m75,83815 498,932.2%   
Fx outflow Rs m30,2242,677 1,129.0%   
Net fx Rs m45,613-2,662 -1,713.5%   
CASH FLOW
From Operations Rs m32,786923 3,551.3%  
From Investments Rs m-17,870317 -5,639.1%  
From Financial Activity Rs m-19,153-481 3,981.8%  
Net Cashflow Rs m-4,239759 -558.4%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 7.2 384.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 30.4 33.6%  
Shareholders   69,601 21,978 316.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 18, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS